Clinical Study
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Table 1
Baseline characteristics of patients.
| | Variable | Total | GLP-1 group | DPP-4 group | Pioglitazone group | P | | (n = 82) | (n = 26) | (n = 36) | (n = 20) |
| | Mean follow-up period (days) | 520 (222–410) | 342 (291–392) | 250 (187–233) | 1236 (378–2216) | <0.01‡ | | Age* (years old) | 54.2 (44.4–63.2) | 55.7 (50.2–62.3) | 54.0 (42.7–64.3) | 52.7 (46.3–59.6) | 0.71† | | Male, n (%) | 61 (74.4%) | 18 (69.2%) | 29 (80.6%) | 14 (70.0%) | 0.55‡ | | Body weight* (kg) | 80.7 (69.1–89.7) | 81.8 (74.4–92.3) | 81.1 (68.4–88.9) | 78.6 (68.2–86.0) | 0.79† | | BMI* (kg/m2) | 29.4 (25.7–31.7) | 30.1 (26.8–32.1) | 29.4 (25.1–31.3) | 28.8 (24.6–31.5) | 0.75† | | Hypertension, n (%) | 41 (50.0%) | 17 (65.4%) | 16 (44.4%) | 8 (40.0%) | 0.17‡ | | Dyslipidemia, n (%) | 57 (69.5%) | 24 (92.3) | 19 (52.8%) | 14 (70.0%) | <0.01‡ | | Smoking, n (%) | 36 (43.9%) | 11 (42.3%) | 16 (44.4%) | 9 (45.0%) | 0.97‡ | | Sulfonylurea agent, n (%) | 40 (48.8%) | 18 (69.2%) | 15 (41.7%) | 7 (35.0%) | 0.04‡ | | Metformin agent, n (%) | 14 (17.1%) | 0 (0%) | 11 (30.6%) | 3 (15.0%) | <0.01‡ | | AST* (IU/mL) | 52 (35–61) | 50 (32–59) | 47 (36–56) | 62 (40–85) | 0.04† | | ALT* (IU/mL) | 75 (55–92) | 65 (52–74) | 75 (55–89) | 87 (60–112) | 0.07† | | -GTP* (IU/mL) | 93 (49–120) | 98 (55–127) | 89 (47–116) | 95 (54–114) | 0.85† | | Fast blood glucose* (mg/dL) | 187 (139–229) | 207 (151–256) | 175 (138–201) | 182 (135–224) | 0.10† | | HbA1c (%) | 8.2 (7.2–9.3) | 8.4 (7.4–9.4) | 8.4 (7.5–9.5) | 7.7 (6.9–8.5) | 0.22† | | LDL-cholesterol* (mg/dL) | 115 (95–140) | 103 (78–116) | 126 (104–148) | 114 (92–140) | 0.02† | | Triglyceride* (mg/dL) | 191 (117–240) | 199 (125–283) | 175 (114–229) | 210 (130–198) | 0.59† | | Platelet count* (/L) | 206 (167–240) | 204 (183–230) | 216 (166 –248) | 192 (147–233) | 0.38† | | APRI index* | 0.75 (0.40–0.95) | 0.73 (0.37–0.91) | 0.64 (0.44–0.76) | 0.96 (0.60–1.09) | 0.04† |
|
|
*Expressed as median (25th–75th percentiles).
†ANOVA.
‡Chi-square tests.
BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; -GTP: γ-glutamyl transpeptidase; HbA1c: hemoglobin A1c; APRI: AST-to-platelet counts ratio index.
|
